CDT Pharma Strategies LLC conducted a poll asking whether partners would renegotiate distribution and dispense fee structures if WAC dropped 50 percent tomorrow.
Public source
Publisher name
Public post
My latest poll closed today. The question was simple. If WAC dropped 50 percent tomorrow, would you renegotiate your distribution and dispense fee structures. Yes immedi…
Company
CDT Pharma Strategies LLC
Market Access & Channel Insights, Strategy + Implementation support for specialty, cell/gene, orphan & retail products
- Industry
- Business Consulting and Services
- Location
- Glenmoore, US
- Company size
- 2–10 employees
About CDT Pharma Strategies LLC
Channel Distribution and Trade (CDT) Pharma Strategies was founded in 2021 and now represents one of the only remaining independent and unaffiliated management consulting resources for manufacturers in the US today. CDT fills the growing need for unbiased real-world market access consultancy to support the full range of products at every stage of the product life cycle. We assist specialty, cell & gene, and branded manufacturers with developing or optimizing their channel strategy. Unlike many consulting firms CDT does not leave a manufacturer following strategy development. CDT can step in and as required implement the strategy as a representative of the manufacturer with the identified channel partners. This execution support with CDT’s deep and diverse experience allows the manufacturer to ensure both flawless execution of the identified strategy and optimization of gross to net costs by ensuring a fair value exchange with channel partners to ensure costs are appropriately allocated to those partners who can actually support demand generation.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Best Practices, LLC
Best Practices, LLC benchmarked research across 22 biopharma leaders found that 71% of Market Access leaders rate payer relationship management as highly effective.
Research & Knowledge
Curatio Advisors
Curatio Advisors analyzed late-stage, self-administered New Molecular Entities (NMEs) using BioLenz to find a mix of 62% Specialty, 28% Tweener, and 9% Retail.
Research & Knowledge
Drug Channels Institute, an HMP Global Company
Drug Channels Institute, an HMP Global Company published a new article on Drug Channels by Tyler Novotny and Bryce Platt, PharmD.
Research & Knowledge
Pharmaceutical Strategies Group - PSG
Pharmaceutical Strategies Group - PSG published an upcoming PBM Customer Satisfaction report based on survey data from payers involving overall PBM satisfaction stabilization in 2026.
Research & Knowledge
Acumetis